Ivora Consulting

Ivora ConsultingIvora ConsultingIvora Consulting

Ivora Consulting

Ivora ConsultingIvora ConsultingIvora Consulting
  • Home
  • About
  • Publications and Patents
    • Publications
    • Patents
    • Presentations
  • Contact
  • More
    • Home
    • About
    • Publications and Patents
      • Publications
      • Patents
      • Presentations
    • Contact
  • Home
  • About
  • Publications and Patents
    • Publications
    • Patents
    • Presentations
  • Contact

Presentations

Posters/Oral Presentations

  1.   “Small molecule inhibitors for precise inhibition of α-synuclein  oligomer generation in Parkinson’s disease (PD)”; Luk, K., Bengoa-Vergniory, N.; Cridland, A.; Li, B.; Ball, S.; Kitchen-Smith, I.; Popovici-Muller, J.; Plowright, A.; Brewerton, S.; Sivasankaran, R.; Thomson,  J.; Habchi, J.; poster #0528 at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders  (AD/PD) Lisbon, Portugal, March 2024. 
  2. “Small molecule inhibitors for precise inhibition of α-synuclein oligomer generation in Parkinson’s disease (PD)”; Cridland, A.; Ball, S.;  Teng, X.; Castellana Cruz, M.; Pisani, K.; Sarracco, E.; Kitchen-Smith,  I.; Meisl, G.; Dear, A.; Yang, X.; Mannini, B.; Jenkins, K.; Popovici-Muller, J.; Plowright, A.; Brewerton, S.; Li, B.; Sivasankaran, R.; Thomson, J.; Habchi, J.; poster #1461 at the MDS International Congress of Parkinson's Disease and Movement Disorders, Copenhagen, Denmark, August 2023. 
  3. “DB-020 Protects Cells from Cisplatin Cytotoxicity in vitro and  Hair Cells in a Guinea Pig Model of Cisplatin Induced Ototoxicity.” Ren, Y.; Moon, C; McCarthy, R.; Xu, Y.; Arsenault, B.; Hu,  Q-Y.; Feng, R.; Popovici-Muller, J.; Lee, J.; Soglia, J.; Silos-Santiago, I.; Shi, F.; PS 463 poster at the ARO Midwinter Meeting, San Jose, CA, January 2020.
  4. “Development of Middle-Ear-Muscle Reflex (MEMR) Biomarker in  Mouse.”  Hickox, A. E.; Senapati, A.; Nguyen, T.; Becker, L.; Smith, L.; Poda, R.; Wang, J.; Zoglio, J.; Hu, Q-Y.; Popovici-Muller, J.;  Silos-Santiago. I.; PS 60 poster at the ARO  Midwinter Meeting, San Jose, CA, January 2020.
  5. “Functional Improvement  and Target Engagement in Mouse Model of Synaptopathy Following Sustained exposure via AAV8-Ntf3 Delivery.”  Nguyen, T., Zhang, X.; Smith, L.; Moon, C., Nguyen, M.; Manna, J.; Pan, N.; Wang, G-P.; Corfas, G.;. Burns,  J.; Popovici-Muller, J.; Silos-Santiago, I.; PS 709 poster at the ARO Midwinter Meeting, Baltimore,  MD, February 2019.
  6. “In vitro Characterization of different AAV-Ntf3s for proof-of-concept in vivo studies.” Moon, C.;      McCarthy, R.; Schwander, M.; Ren, Y.; Wang, G-P.; Corfas, G.; Popovici-Muller, J.; Silos-Santiago, I.; PS 469 poster at the ARO Midwinter Meeting, Baltimore, MD, February 2019.
  7. “Vgf expression is  a biomarker of NTF3 target engagement in mouse spiral ganglion neurons in    vitro and in vivo.” Yang, T.; Moon, C.; Nguyen, M.; Wang, G-P.; So, K.; Pregernig, G.; Nguyen, T.;    Manna, J.; McCarthy, R.; Druckenbrod, N.; Kohrman, D.; Palermo, A.; Corfas, G.; Popovici-Muller, J.; Silos-Santiago, I.; Burns, J. C.;  oral presentation at the ARO Midwinter Meeting, Baltimore, MD, February 2019.
  8. “Development of Robust In Vitro and Ex Vivo Assays to Support Drug Discovery Programs.” McCarthy, R.; Moon, C.; Yang, T.; Druckenbrod, N.; Alterman, E.; Ren, Y.; Burns, J.; Popovici-Muller,  J.; Silos-Santiago, I.; PS 707 poster at the ARO Midwinter Meeting, Baltimore, MD, February 2019.
  9. “Discovery of preclinical candidate SCH 900577: A prodrug of hydantoin based TACE  inhibitor.”  Tong, L.; Kim, S. H.; Chen, L.; Kosinski, A.; Shankar, B.; Girijavallabhan, V.; Yang, D-Y.; Yu, W.; Zhou, G.; Shih, N-Y.; Rosner, K.; Li, D.; Dai, C.; Popovici-Muller, J.; Yang, L.; Siddiqui, A.; Guo, Z.; Orth, P.; Chen, S.; Hu, M.;  Lundell, D.; Niu, X.; Umland, S.; Kozlowski, J. A.; MEDI-248 at ACS National Meeting San Francisco , CA, April 2017.
  10. “Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations.” Popovici-Muller, J.; Lemieux, R.; Saunders, J.; Salituro, F.; Yen, K.; Straley, K.; Tobin, E.; Wang, F.;  Gross, S.; Artin, E.; Dang, L.; Yang, H.; Utley, L.; Chen, Y.; Olaharski, A.; Silverman, L.; Agresta, S.; Su, M.; Biller, S.; MEDI-268, oral presentation at the  ACS      National Meeting Philadelphia, PA,  August 2016.
  11. “Preclinical  pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate      kinase-R activator”. Chen, Y.; Nagaraja, R.; Le, K.; Kosinski, P. A.; Histen, G.; Kung, C.; Kim, H.; Prakash, C.; Dang, L.; Popovici-Muller, J.; Hixon, J.; Silverman, L.; Biller, S.; Yang, H.; EHA-1960 oral presentation at the 21st Congress of the  European Hematology Association, Copenhagen, Denmark, June 2016.
  12. “AG-519 is a potent activator of mutant pyruvate kinase associated with hemolytic anemia”.      Hixon, J.; Kosinski, P. A.; Clasquin, M.; Johnson, K.; Popovici-Muller, J.; Zahler, B.; Cianchetta, G.; Silverman, L.; Dang, L.; Kung, C.; EHA-1397 poster at the 21st  Congress of the European Hematology Association, Copenhagen, Denmark, June  2016.
  13. “Discovery of AG-221: A  first-in-class inhibitor of IDH2 mutant enzymes for the treatment of acute myelogenous leukemia”. Travins, J. M.; Saunders, J.; Salituro, F. G.; Popovici-Muller, J. V.; Yen, K.; Straley, K.; Hansen,  E.; Wang, F.; Gross, S.; Dang, L.; Yang, H.;  Utley, L.; Chen, Y.; Silverman, L.; Agresta, S.; Su, M.; Biller, S. A.;  MEDI-343, oral presentation at the ACS National Meeting, Boston, MA,  August 2015.
  14. “AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of  Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular  Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo.” Hansen, E.; Quivoron, C.; Straley, K.; Lemieux, R. E.; Popovici-Muller, J.; Sadrzadeh, H.; Fathi, A. T.; Gliser,  C.; David, M.; Saada, V.; Micol, J. B.; Bernard, O.; Dorsch, M.; Yang, H.; Su,  M.; Agresta, S.; de Botton, S.; Penard-Lacronique, V.; Yen. K.; Abstract 3734 poster at ASH Annual Meeting, San Francisco, CA, December 2014.
  15. “IDH1 mutant inhibitor  induces cellular differentiation and offers a combination benefit with      Ara-C in a primary human Idh1 mutant AML xenograft model.” Yen, K. E.;  Chen, Y.; Wang, F.; Lemieux, R.; Popovici-Muller,  J.; Yang, H.; Straley, S.; Choe, S.; Dorsch, M.; Agresta, S.;      Schenkein, D.; Biller, S.; Su, M. Abstract 1194, poster at AACR Annual  Meeting, San Diego, CA, April 2014.
  16. “IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit with Ara-C In a Primary Human Idh1 Mutant AML  Xenograft Model”. Yen, K. E.; Lemieux, R.; Popovici-Muller, J.; Chen, Y.; Yang, H.; Kim, H.; Choe, S.; Straley, S.; Dorsch, M.; Agresta, S.; Schenkein, D.; Biller, S.; Su, M. Wang, F.; Abstract 3946 poster at  ASH Annual Meeting, New Orleans, LA, December 2013.
  17. “Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia.” Kung, C.; Hixon, J.; Kosinski, P.; Histen, G.;  Hill, C.; Si, Y.; Kernytsky, A.; Chen, Y.; DeLaBarre, B.; Clasquin, M.; Ho, H.; Cossor, F. I.; Neufeld, E. J.;  Salituro, F.; Popovici-Muller, J.;  Agresta, S .; Silverman, L.; Dang, L.; Abstract 2180 poster at  ASH Annual Meeting, New Orleans, LA , December 2013.
  18. “Discovery of mutant IDH2  inhibitors for the treatment of cancer.“ Travins, J. M.; Popovici-Muller, J; DeLaBarre, B.;  Gross, S.; Yang, H.; Wang, F.; Yen, K. E.; Salituro, F. G.; Saunders, J.      O.; Dang, L.; Biller, S. A. MEDI-200, oral presentation at the ACS National Meeting, Indianapolis, IN, September 2013.
  19. “Structure and activity relationships of tartrate-based TACE inhibitors.“ Li, D.; Popovici-Muller, J; Belanger, D. B.; Caldwell, J.; Dai, C.; David, M.; Girijavallabhan, V. M.; Guo, Z.; Kozlowski, J.A.; Lavey, B. J.;  Lundell, D. J.; Lee, J. F.; Liu, Z.; Mazzola, R.; McKittrick, B.; Niu, X.;  Orth, P.; Madison, V.; Piwinski, J.; Rizvi, R.; Rosner, K. E.; Shankar, B.; Shih, N-Y.; Shipps, G. W.; Siddiqui, M. A.; Spitler, J.; Strickland,  C. O.; Sun, J.; Ting, P. C.; Chen, S.; Vaccaro, H.; Yu, W.; Zhou, G.; Zhu, Z.; MEDI-166 poster at ACS National Meeting, Boston, MA, August 2010. 
  20. “Novel approaches to CDK2 modulation: Hit identification, characterization, and optimization .“    Deng, Y.; Shipps, G. W.; Curran, P. J.; Zhao, L.; Siddiqui, M. A.; Popovici-Muller, J.; Duca, J. S.;  Hruza, A. W.; Fischmann, T. O.; Madison, V. S.; Zhang, R.; McNemar, C. W.;  Mayhood, T. W.; Lees, E. M.; Parry, D. A.; Windsor, W. T. MEDI-182 poster at the ACS National Meeting, Boston, MA, August 2010.
  21. “Discovery  of novel tartrate-based TNF-α converting enzyme (TACE) inhibitors.” Rosner, K. E.; Guo, Z.; Orth, P.; Shipps, G. W.; Belanger, D. B.; Chan, T. Y.; Curran, P. J.; Dai, C .; Deng, Y.; Girijavallabhan, V. M.; Hong, L.; Lavey, B. J.; Lee, J. F.; Li, D.; Popovici-Muller, J.; Ting, P. C.;      Vaccaro, H.; Wang, L.; Wang, T.; Yu, W.; Zhou, G.; Niu, X.; Sun, J.;   Kozlowski, J. A.; Lundell, D. J.; Madison, V.; McKittrick, B.; Piwinski,  J. J.; Shih, N-Y; Siddiqui, M. A.; Strickland, C. O.; Liu, Z. MEDI-515, poster at the ACS National Meeting, San Francisco, CA,  March 2010.
  22. “Structure-based design of TACE inhibitors.” Kozlowski, J. A.; Yu, W.; Guo, Z.; Orth, P.; Chen, L.; Dai, C.;  Feltz, R. J.; Girijavallabhan, V. M.; Kim, S. H.; Lavey, B. J.; Li, D.; Lundell, D.; Niu, X.; Piwinski, J. J.; Popovici-Muller, J.; Rizvi, R.; Rosner, K. E.; Shankar, B. B.;  Shih, N-Y; Siddiqui, M. A.; Su, J.; Tong, L.; Umland, S.; Wong, M. K.;  Yang, D-Y.; Zhou, G. MEDI-512, poster at the ACS National Meeting, San Francisco, CA, March 2010.
  23. “Substituted 5-oxopyrazoles as HCV polymerase inhibitors.” Wang, T.; Li, D.; Shipps, G. W.;      Rosner, K. E.; Curran, P.; Deng, Y.; Popovici-Muller, J.; Cooper, A. B.; Girijavallabhan, V.; MEDI-083, poster at the ACS National Meeting, Boston, MA, August 2007.
  24. “Pyrazolopyrimidines as inhibitors of HCV RNA polymerase.” Popovici-Muller, J.; Shipps, G.      W.; Rosner, K. E.; Deng, Y.; Wang, T.; Curran, P. J.; Brown, M. A.; Cooper, A. B.; Girijavallabhan, V.; Butkiewicz, N.; Cable, M.; MEDI 337, poster at the ACS National Meeting, San Diego, CA, March 2005.
  25. “Substituted  4H-Pyrazolo[1,5-a]pyrimidin-7-ones as Hepatitis C Virus Polymerase  Inhibitors.” Deng, Y.; Popovici-Muller, J.; Shipps, G. W.; Rosner, K. E.; Wang, T.; Curran, P. J.; Cooper, A.  B.; Girijavallabhan, V.; Butkiewicz, N.; Cable, M.; MEDI 340, poster at the ACS National Meeting, San Diego, CA, March 2005.
  26. “A  Benzobicyclo[4.2.1]nonene Model System for Study of Carbocation-Pi Interaction.” Popovici-Muller, J. V.; Ditchfield, R. and Spencer, T. A.; ORGN 508, oral presentation  at the ACS National Meeting, San Francisco, CA, March 2000.

Copyright © 2025 Ivora Consulting - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept